The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- BMC cancer
- Publicado em
- 25 ago 2025
- Citações
- 3
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy
Hui Wu, Wenzhi Shu, Yongfeng Ding, Qiong Li, Ning Li, Qiyue Wang, Yinqi Chen, Yuejun Han, Dongdong Huang, Haiping Jiang
Descritores MeSH
- Esophagogastric Junction
- Antineoplastic Combined Chemotherapy Protocols
- Esophageal Neoplasms
- Stomach Neoplasms
- Immune Checkpoint Inhibitors
- Humans
- Male
- Middle Aged
- Prognosis
- Biomarkers, Tumor
Veja também
Estudos relacionados
- Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis
- The efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
- PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis
- The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis